

### Tozinameran

S

#### Relapse of adult-onset Still's disease: case report

A 37-year-old woman developed relapse of adult-onset Still's disease (AOSD) following coronavirus disease-2019 (COVID-19) vaccination with tozinameran.

The woman presented with a 2-month history of polyarthritis, rash, episodic fever and sore throat. The symptoms had occurred a few days after she had received a second dose of tozinameran [BNT162b2 COVID-19 mRNA vaccine; manufactured by Pfizer-BioNTech; *route and dosage not stated*]. She was diagnosed with AOSD 13 years prior and had reported repeated relapses and remissions. Upon presentation, joint examination revealed tenderness and swelling of multiple joints bilaterally. Skin examination showed a salmon-pink maculopapular eruption on her legs and arms, which was most evident at fever peak. Laboratory tests revealed WBC of  $9.8 \times 10^3$  cells/ $\mu$ L, CRP of 21.6 mg/L, neutrophils 77.2% and LDH of 325 U/L. A CT scan showed generalised lymphadenopathy. Her symptoms, consisting rash, sore throat, fever, polyarthritis, and enlarged lymph nodes, were similar to her earlier AOSD flare-ups. Hence, she was diagnosed with a relapse of AOSD secondary to tozinameran [*duration of treatment to reaction onset not stated*].

The woman started receiving prednisolone during hospitalisation, which resulted in partial relief of her symptoms. After starting tocilizumab, there was a resolution of her symptoms. She did not report further AOSD relapse during her follow up for 2 months.

Yamamoto S, et al. Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine. *Clinical and Experimental Rheumatology* 39: S139-S140, No. 5, 2021. Available from: URL: <https://www.clinexprheumatol.org/a.asp?IDArchivio=253>

803659314